Amifampridines (3,4 Diaminopyridine and 3,4 Diaminopyridine Phosphate): Drugs of Choice for Lambert-Eaton Myasthenic Syndrome

Shin J Oh
{"title":"Amifampridines (3,4 Diaminopyridine and 3,4 Diaminopyridine Phosphate): Drugs of Choice for Lambert-Eaton Myasthenic Syndrome","authors":"Shin J Oh","doi":"10.35248/2329-9096.21.S4.005","DOIUrl":null,"url":null,"abstract":"Amifampridines have been known to be effective as symptomatic treatment of Lambert-Eaton myasthenic syndrome since 1983. Food Drug Administration (FDA) approved amifampridines, the most studied safe and effective drugs in the neuromuscular diseases, are available for the general use for symptomatic treatment of LEMS, 60 years after the first description of LEMS and 40 years after the first trial of 3,4-DAP in LEMS.","PeriodicalId":14201,"journal":{"name":"International Journal of Physical Medicine and Rehabilitation","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Physical Medicine and Rehabilitation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/2329-9096.21.S4.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Amifampridines have been known to be effective as symptomatic treatment of Lambert-Eaton myasthenic syndrome since 1983. Food Drug Administration (FDA) approved amifampridines, the most studied safe and effective drugs in the neuromuscular diseases, are available for the general use for symptomatic treatment of LEMS, 60 years after the first description of LEMS and 40 years after the first trial of 3,4-DAP in LEMS.
氨苯丙啶(3,4二氨基吡啶和3,4磷酸二氨基吡啶):兰伯特-伊顿肌无力综合征的首选药物
自1983年以来,阿米福定被认为是有效的兰伯特-伊顿肌无力综合征的对症治疗。amifampri定是美国食品药品监督管理局(FDA)批准的神经肌肉疾病中研究最多的安全有效的药物,在LEMS首次描述60年后,在3,4- dap在LEMS中的首次试验40年后,可用于LEMS的一般对症治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信